By: IPP Bureau
Last updated : October 01, 2025 9:04 am
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
ACL Digital, a global leader in digital product innovation and engineering services, announced the acquisition of Symbiance, a US-based, data-driven, technology-enabled Contract Research Organization (CRO). With over three decades of expertise in clinical data services, operations, medical monitoring, project management, medical writing, and pharmacovigilance, Symbiance adds significant strength to ACL Digital’s life sciences portfolio.
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions. By integrating Symbiance’s deep domain expertise in clinical data management, data standardization, biostatistics, statistical programming, medical writing, and pharmacovigilance, ACL Digital will further scale its ability to deliver AI-powered, patient-centric solutions for pharmaceutical, biotech, and medical device companies worldwide.
Ramandeep Singh, CEO of ACL Digital, said: “We are delighted to welcome Symbiance to ACL Digital. This acquisition is a major step forward in our growth strategy, expanding our clinical research capabilities while reinforcing our commitment to transformative, patient-centric solutions. By combining ACL Digital’s AI-powered offerings with Symbiance’s proven clinical research expertise, we will accelerate innovation, improve operational efficiency, and help organizations adopt intelligent, data-driven solutions that drive better outcomes.”
Sreejith Narayanan, Senior Vice President of Sales and Operations at ACL Digital, added:
“Symbiance has earned a strong reputation in the U.S. for its consistent focus on quality and delivery. Their success reflects both the leadership’s vision and the expertise of their team. Together, we are strengthening ACL Digital’s position as a global leader in digital solutions for clinical research and enabling our clients to stay future-ready.”
Ilango Ramanujam, President & CEO of Symbiance, said: “We are excited to join ACL Digital and contribute to its continued success. Symbiance’s unique ‘people + product’ delivery model, supported by proprietary tools and AI-powered analytics, will further enhance ACL Digital’s service offerings. Together, we will deliver even greater value to our clients while advancing the quality of clinical research services globally.”